Interleukin	B-protein
2	I-protein
receptor	I-protein
(	O
Tac	B-protein
antigen	I-protein
)	O
expression	O
in	O
HTLV-I-associated	O
adult	O
T-cell	B-cell_type
leukemia	O
.	O

Interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
is	O
a	O
lymphokine	B-protein
synthesized	O
by	O
some	O
T-cells	B-cell_type
following	O
activation	O
.	O

Resting	O
T-cells	B-cell_type
do	O
not	O
express	O
IL-2	B-protein
receptors	I-protein
,	O
but	O
receptors	O
are	O
rapidly	O
expressed	O
on	O
T-cells	B-cell_type
following	O
interaction	O
of	O
antigens	O
,	O
mitogens	O
,	O
or	O
monoclonal	B-protein
antibodies	I-protein
with	O
the	O
antigen-specific	B-protein
T-cell	I-protein
receptor	I-protein
complex	I-protein
.	O

Using	O
anti-Tac	B-protein
,	O
a	O
monoclonal	B-protein
antibody	I-protein
that	O
recognizes	O
the	O
IL-2	B-protein
receptor	I-protein
,	O
the	O
receptor	O
has	O
been	O
purified	O
and	O
shown	O
to	O
be	O
a	O
Mr	O
33	O
,	O
000	O
peptide	O
that	O
is	O
posttranslationally	O
glycosylated	O
to	O
a	O
Mr	O
55	O
,	O
000	O
mature	O
form	O
.	O

Normal	O
resting	O
T-cells	B-cell_type
and	O
most	O
leukemic	B-cell_line
T-cell	I-cell_line
populations	I-cell_line
do	O
not	O
express	O
IL-2	B-protein
receptors	I-protein
;	O
however	O
,	O
the	O
leukemic	B-cell_type
cells	I-cell_type
of	O
the	O
11	O
patients	O
examined	O
who	O
had	O
human	O
T-cell	O
lymphotropic	O
virus-associated	O
adult	O
T-cell	O
leukemia	O
expressed	O
the	O
Tac	B-protein
antigen	I-protein
.	O

In	O
human	B-cell_type
T-cell	I-cell_type
lymphotropic	I-cell_type
virus-I	I-cell_type
infected	I-cell_type
cells	I-cell_type
,	O
the	O
Mr	O
42	O
,	O
000	O
long	O
open	B-protein
reading	I-protein
frame	I-protein
protein	I-protein
encoded	O
in	O
part	O
by	O
the	O
pX	B-DNA
region	I-DNA
of	O
this	O
virus	O
may	O
act	O
as	O
a	O
transacting	B-protein
transcriptional	I-protein
activator	I-protein
that	O
induces	O
IL-2	B-DNA
receptor	I-DNA
gene	I-DNA
transcription	O
,	O
thus	O
providing	O
an	O
explanation	O
for	O
the	O
constant	O
association	O
of	O
IL-2	B-protein
receptor	I-protein
expression	O
with	O
adult	O
T-cell	O
lymphotropic	O
virus-I	O
infection	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

The	O
constant	O
expression	O
of	O
large	O
numbers	O
of	O
IL-2	B-protein
receptors	I-protein
which	O
may	O
be	O
aberrant	O
may	O
play	O
a	O
role	O
in	O
the	O
uncontrolled	O
growth	O
of	O
adult	B-cell_type
T-cell	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

Two	O
patients	O
with	O
Tac-positive	O
adult	O
T-cell	O
leukemia	O
have	O
been	O
treated	O
with	O
the	O
anti-Tac	B-protein
.	O

One	O
of	O
the	O
patients	O
had	O
6-	O
and	O
3-mo	O
remissions	O
of	O
his	O
leukemia	O
following	O
two	O
courses	O
of	O
therapy	O
with	O
this	O
monoclonal	B-protein
antibody	I-protein
directed	O
toward	O
this	O
growth	B-protein
factor	I-protein
receptor	I-protein
.	O

[	NULL
CANCER	NULL
RESEARCH	NULL
(	NULL
SUPPL	NULL
)	NULL
45	NULL
,	NULL
45595-45625	NULL
,	NULL
September	NULL
1985	NULL
]	NULL
Interleukin	NULL
2	NULL
Receptor	NULL
(	NULL
Tac	NULL
Antigen	NULL
)	NULL
Expression	NULL
in	NULL
HTLV-l-associated	NULL
Adult	NULL
T-Cell	NULL
Leukemia	NULL
Thomas	NULL
A.	NULL
Waldmann	NULL
,	NULL
Dan	NULL
L.	NULL
Longo	NULL
,	NULL
Warren	NULL
J.	NULL
Leonard	NULL
,	NULL
Joel	NULL
M.	NULL
Depper	NULL
,	NULL
Craig	NULL
B.	NULL
Thompson	NULL
,	NULL
Martin	NULL
Kronke	NULL
,	NULL
Carolyn	NULL
K.	NULL
Goldman	NULL
,	NULL
Susan	NULL
Sharrow	NULL
,	NULL
Kathleen	NULL
Bongiovanni	NULL
,	NULL
and	NULL
Warner	NULL
C.	NULL
Greene	NULL
Metabolism	NULL
,	NULL
Medicine	NULL
,	NULL
and	NULL
Immunology	NULL
Branches	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
NIH	NULL
,	NULL
Naval	NULL
Medical	NULL
Research	NULL
Institute	NULL
,	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
20205	NULL
Abstract	NULL
Interieukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
is	NULL
a	NULL
lymphokine	NULL
synthesized	NULL
by	NULL
some	NULL
T-cells	NULL
following	NULL
activation	NULL
.	NULL

Resting	NULL
T-cells	NULL
do	NULL
not	NULL
express	NULL
IL-2	NULL
receptors	NULL
,	NULL
but	NULL
receptors	NULL
are	NULL
rapidly	NULL
expressed	NULL
on	NULL
T-cells	NULL
following	NULL
interaction	NULL
of	NULL
antigens	NULL
,	NULL
mitogens	NULL
,	NULL
or	NULL
monoclonal	NULL
antibodies	NULL
with	NULL
the	NULL
antigen-specific	NULL
T-cell	NULL
receptor	NULL
complex	NULL
.	NULL

Using	NULL
anti-T	NULL
ac	NULL
,	NULL
a	NULL
monoclonal	NULL
antibody	NULL
that	NULL
recognizes	NULL
the	NULL
IL-2	NULL
receptor	NULL
,	NULL
the	NULL
receptor	NULL
has	NULL
been	NULL
purified	NULL
and	NULL
shown	NULL
to	NULL
be	NULL
a	NULL
M	NULL
,	NULL
33,000	NULL
peptide	NULL
that	NULL
is	NULL
posttranslationally	NULL
glycosylated	NULL
to	NULL
a	NULL
M	NULL
,	NULL
55,000	NULL
mature	NULL
form	NULL
.	NULL

Normal	NULL
resting	NULL
T-cells	NULL
and	NULL
most	NULL
leukemic	NULL
T-cell	NULL
populations	NULL
do	NULL
not	NULL
express	NULL
IL-2	NULL
receptors	NULL
;	NULL
however	NULL
,	NULL
the	NULL
leukemic	NULL
cells	NULL
of	NULL
the	NULL
11	NULL
patients	NULL
examined	NULL
who	NULL
had	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
virus-associated	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
expressed	NULL
the	NULL
Tac	NULL
antigen	NULL
.	NULL

in	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
virus-l	NULL
infected	NULL
cells	NULL
,	NULL
the	NULL
M	NULL
,	NULL
42,000	NULL
long	NULL
open	NULL
reading	NULL
frame	NULL
protein	NULL
encoded	NULL
in	NULL
part	NULL
by	NULL
the	NULL
pxX	NULL
region	NULL
of	NULL
this	NULL
virus	NULL
may	NULL
act	NULL
as	NULL
a	NULL
transacting	NULL
transcriptional	NULL
activator	NULL
that	NULL
induces	NULL
IL-2	NULL
receptor	NULL
gene	NULL
transcription	NULL
,	NULL
thus	NULL
providing	NULL
an	NULL
explanation	NULL
for	NULL
the	NULL
constant	NULL
association	NULL
of	NULL
IL-2	NULL
receptor	NULL
expression	NULL
with	NULL
adult	NULL
T-cell	NULL
lymphotropic	NULL
virus-	NULL
!	NULL

infection	NULL
of	NULL
lymphoid	NULL
cells	NULL
.	NULL

The	NULL
constant	NULL
expression	NULL
of	NULL
large	NULL
numbers	NULL
of	NULL
IL-2	NULL
receptors	NULL
which	NULL
may	NULL
be	NULL
aberrant	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
uncontrolled	NULL
growth	NULL
of	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
cells	NULL
.	NULL

Two	NULL
patients	NULL
with	NULL
Tac-positive	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
have	NULL
been	NULL
treated	NULL
with	NULL
the	NULL
anti-Tac	NULL
.	NULL

One	NULL
of	NULL
the	NULL
patients	NULL
had	NULL
6-	NULL
and	NULL
3-mo	NULL
remissions	NULL
of	NULL
his	NULL
leukemia	NULL
following	NULL
two	NULL
courses	NULL
of	NULL
therapy	NULL
with	NULL
this	NULL
monoclonal	NULL
antibody	NULL
directed	NULL
toward	NULL
this	NULL
growth	NULL
factor	NULL
receptor	NULL
.	NULL

Introduction	NULL
The	NULL
induction	NULL
of	NULL
an	NULL
immune	NULL
response	NULL
to	NULL
a	NULL
foreign	NULL
antigen	NULL
requires	NULL
the	NULL
activation	NULL
of	NULL
T-lymphocytes	NULL
with	NULL
receptors	NULL
for	NULL
the	NULL
specific	NULL
antigen	NULL
.	NULL

The	NULL
human	NULL
antigen-specific	NULL
T-cell	NULL
receptor	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
a	NULL
M	NULL
,	NULL
90,000	NULL
polymorphic	NULL
heterodimer	NULL
of	NULL
a	NULL
and	NULL
3	NULL
chains	NULL
of	NULL
approximately	NULL
molecular	NULL
weight	NULL
of	NULL
40,000	NULL
to	NULL
50,000	NULL
associated	NULL
with	NULL
three	NULL
nonpolymorphic	NULL
peptide	NULL
chains	NULL
of	NULL
molecular	NULL
weight	NULL
of	NULL
20,000	NULL
to	NULL
28,000	NULL
identified	NULL
by	NULL
the	NULL
T-3	NULL
monoclonal	NULL
antibody	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

T-cell	NULL
activation	NULL
is	NULL
initiated	NULL
following	NULL
the	NULL
interaction	NULL
of	NULL
antigen	NULL
with	NULL
this	NULL
complex	NULL
antigen-specific	NULL
T-cell	NULL
receptor	NULL
.	NULL

Two	NULL
principal	NULL
events	NULL
occur	NULL
at	NULL
this	NULL
point	NULL
which	NULL
are	NULL
required	NULL
for	NULL
T-cell	NULL
proliferation	NULL
and	NULL
the	NULL
development	NULL
of	NULL
functionally	NULL
active	NULL
effector	NULL
T-cells	NULL
.	NULL

First	NULL
,	NULL
following	NULL
interaction	NULL
with	NULL
antigen	NULL
and	NULL
the	NULL
macrophage-derived	NULL
interleukin-1	NULL
,	NULL
T-cells	NULL
synthesize	NULL
and	NULL
secrete	NULL
the	NULL
lymphokine	NULL
IL-2	NULL
``	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
exert	NULL
its	NULL
biological	NULL
effects	NULL
,	NULL
IL-2	NULL
must	NULL
interact	NULL
with	NULL
high-affinity-specific	NULL
membrane	NULL
receptors	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Resting	NULL
T-cells	NULL
do	NULL
not	NULL
express	NULL
IL-2	NULL
receptors	NULL
,	NULL
but	NULL
*	NULL
Presented	NULL
at	NULL
the	NULL
HTLV	NULL
Symposium	NULL
,	NULL
December	NULL
6	NULL
and	NULL
7	NULL
,	NULL
1984	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
IL-2	NULL
,	NULL
interleukin-2	NULL
;	NULL
PHA	NULL
,	NULL
phytohemagglutinin	NULL
;	NULL
HTLV	NULL
,	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
;	NULL
ATL	NULL
,	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
;	NULL
FITC	NULL
,	NULL
fluores-cein	NULL
isothiocyanate	NULL
;	NULL
LTR	NULL
,	NULL
long	NULL
terminal	NULL
repeat	NULL
;	NULL
LOR	NULL
,	NULL
long	NULL
open	NULL
reading	NULL
frame	NULL
;	NULL
ProMACE-MOPP	NULL
,	NULL
predisone	NULL
,	NULL
cyclophosphamide	NULL
,	NULL
doxorubicin	NULL
,	NULL
VP-16	NULL
,	NULL
methotrex-ate	NULL
with	NULL
leucovorin	NULL
rescue	NULL
.	NULL

receptors	NULL
are	NULL
rapidly	NULL
expressed	NULL
on	NULL
T-cells	NULL
following	NULL
activation	NULL
with	NULL
antigen	NULL
or	NULL
mitogen	NULL
.	NULL

Thus	NULL
,	NULL
both	NULL
the	NULL
growth	NULL
factor	NULL
interleukin-2	NULL
and	NULL
its	NULL
receptor	NULL
are	NULL
absent	NULL
in	NULL
resting	NULL
T-cells	NULL
,	NULL
but	NULL
following	NULL
activation	NULL
,	NULL
the	NULL
genes	NULL
for	NULL
both	NULL
proteins	NULL
become	NULL
expressed	NULL
.	NULL

Thus	NULL
,	NULL
both	NULL
the	NULL
production	NULL
of	NULL
interleukin-2	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
interleukin-2	NULL
receptors	NULL
are	NULL
pivotal	NULL
events	NULL
in	NULL
the	NULL
full	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
immune	NULL
response	NULL
.	NULL

While	NULL
the	NULL
antigen	NULL
confers	NULL
specificity	NULL
for	NULL
a	NULL
given	NULL
immune	NULL
response	NULL
,	NULL
the	NULL
interaction	NULL
of	NULL
IL-2	NULL
and	NULL
IL-2	NULL
receptors	NULL
determines	NULL
its	NULL
magnitude	NULL
and	NULL
duration	NULL
.	NULL

The	NULL
specific	NULL
membrane	NULL
receptor	NULL
for	NULL
IL-2	NULL
on	NULL
human	NULL
lymphocytes	NULL
has	NULL
been	NULL
identified	NULL
using	NULL
a	NULL
monoclonal	NULL
antibody	NULL
(	NULL
anti-T	NULL
ac	NULL
)	NULL
directed	NULL
towards	NULL
this	NULL
molecule	NULL
(	NULL
7-9	NULL
)	NULL
.	NULL

The	NULL
anti-Tac	NULL
monoclonal	NULL
antibody	NULL
,	NULL
prepared	NULL
by	NULL
Uchiyama	NULL
et	NULL
al	NULL
.	NULL

(	NULL
7	NULL
)	NULL
,	NULL
was	NULL
selected	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
its	NULL
ability	NULL
to	NULL
bind	NULL
to	NULL
activated	NULL
T-cells	NULL
but	NULL
not	NULL
to	NULL
resting	NULL
T-cells	NULL
,	NULL
B-cells	NULL
,	NULL
or	NULL
monocytes	NULL
.	NULL

This	NULL
pattern	NULL
of	NULL
cellular	NULL
reactivity	NULL
was	NULL
identical	NULL
with	NULL
the	NULL
distribution	NULL
of	NULL
IL-2	NULL
receptors	NULL
reported	NULL
by	NULL
Robb	NULL
et	NULL
al	NULL
.	NULL

(	NULL
6	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
hypothesized	NULL
that	NULL
anti-Tac	NULL
recognizes	NULL
the	NULL
human	NULL
receptor	NULL
for	NULL
IL-2	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
.	NULL

Data	NULL
in	NULL
support	NULL
of	NULL
this	NULL
hypothesis	NULL
are	NULL
as	NULL
follows	NULL
:	NULL
anti-T	NULL
ac	NULL
blocks	NULL
the	NULL
IL-2-induced	NULL
DNA	NULL
synthesis	NULL
of	NULL
IL-2-dependent	NULL
continuous	NULL
T-cell	NULL
lines	NULL
but	NULL
does	NULL
not	NULL
inhibit	NULL
DNA	NULL
synthesis	NULL
of	NULL
1L-2-independent	NULL
T-cell	NULL
lines	NULL
;	NULL
anti-Tac	NULL
blocks	NULL
over	NULL
95	NULL
%	NULL
of	NULL
the	NULL
binding	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
IL-2	NULL
to	NULL
HUT	NULL
102-B2	NULL
cells	NULL
and	NULL
PHA-activated	NULL
lymphoblasts	NULL
;	NULL
and	NULL
IL-2	NULL
at	NULL
high	NULL
concentration	NULL
blocks	NULL
the	NULL
binding	NULL
of	NULL
H-labeled	NULL
anti-T	NULL
ac	NULL
to	NULL
PHA-activated	NULL
lym-phoblasts	NULL
.	NULL

The	NULL
requirement	NULL
for	NULL
high	NULL
concentrations	NULL
of	NULL
IL-2	NULL
is	NULL
explained	NULL
by	NULL
the	NULL
observation	NULL
that	NULL
anti-T	NULL
ac	NULL
identifies	NULL
two	NULL
species	NULL
of	NULL
IL-2	NULL
receptors	NULL
,	NULL
one	NULL
with	NULL
a	NULL
high	NULL
(	NULL
107	NULL
m	NULL
)	NULL
and	NULL
one	NULL
with	NULL
a	NULL
lower	NULL
affinity	NULL
of	NULL
IL-2	NULL
binding	NULL
.	NULL

Furthermore	NULL
,	NULL
Robb	NULL
and	NULL
Greene	NULL
(	NULL
10	NULL
)	NULL
demonstrated	NULL
that	NULL
an	NULL
initial	NULL
passage	NULL
of	NULL
radiolabeled	NULL
proteins	NULL
from	NULL
PHA	NULL
lymphoblasts	NULL
through	NULL
either	NULL
an	NULL
IL-2-coupled	NULL
affinity	NULL
support	NULL
or	NULL
a	NULL
column	NULL
of	NULL
anti-T	NULL
ac	NULL
coupled	NULL
to	NULL
Sepharose	NULL
effectively	NULL
removed	NULL
molecules	NULL
reactive	NULL
with	NULL
the	NULL
alternative	NULL
support	NULL
.	NULL

Thus	NULL
,	NULL
under	NULL
the	NULL
conditions	NULL
used	NULL
,	NULL
all	NULL
anti-Tac-reactive	NULL
molecules	NULL
appeared	NULL
capable	NULL
of	NULL
binding	NULL
IL-2	NULL
,	NULL
and	NULL
the	NULL
ability	NULL
to	NULL
bind	NULL
IL-2	NULL
was	NULL
limited	NULL
to	NULL
the	NULL
Tac	NULL
protein	NULL
.	NULL

Utilizing	NULL
the	NULL
anti-T	NULL
ac	NULL
monoclonal	NULL
antibody	NULL
,	NULL
we	NULL
have	NULL
defined	NULL
a	NULL
variety	NULL
of	NULL
T-	NULL
and	NULL
B-lymphocyte	NULL
functions	NULL
that	NULL
require	NULL
an	NULL
interaction	NULL
of	NULL
IL-2	NULL
with	NULL
its	NULL
inducible	NULL
receptor	NULL
on	NULL
activated	NULL
lymphocytes	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
anti-Tac	NULL
to	NULL
in	NULL
vitro	NULL
culture	NULL
systems	NULL
blocked	NULL
the	NULL
IL-2-induced	NULL
DNA	NULL
synthesis	NULL
of	NULL
IL-2-dependent	NULL
T-cell	NULL
lines	NULL
and	NULL
inhibited	NULL
soluble	NULL
auto-	NULL
and	NULL
alloantigen-induced	NULL
T-cell	NULL
proliferation	NULL
.	NULL

Furthermore	NULL
,	NULL
it	NULL
abrogated	NULL
the	NULL
generation	NULL
of	NULL
cytotoxic	NULL
and	NULL
suppressor	NULL
effector	NULL
T-cells	NULL
but	NULL
did	NULL
not	NULL
inhibit	NULL
their	NULL
action	NULL
once	NULL
generated	NULL
.	NULL

The	NULL
anti-receptor	NULL
antibody	NULL
also	NULL
inhibited	NULL
the	NULL
proliferation	NULL
and	NULL
immunoglobulin	NULL
synthesis	NULL
of	NULL
purified	NULL
B-cells	NULL
stimulated	NULL
with	NULL
Staphylococcus	NULL
Cowan	NULL
strain	NULL
|	NULL
organisms	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
the	NULL
anti-Tac	NULL
monoclonal	NULL
antibody	NULL
was	NULL
used	NULL
to	NULL
characterize	NULL
IL-2	NULL
receptor	NULL
expression	NULL
in	NULL
HTLV-l-associated	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
report	NULL
the	NULL
initial	NULL
results	NULL
of	NULL
a	NULL
clinical	NULL
trial	NULL
to	NULL
evaluate	NULL
the	NULL
efficacy	NULL
of	NULL
i.v	NULL
.	NULL

administered	NULL
CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

45	NULL
SEPTEMBER	NULL
1985	NULL
4559s	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1985	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

IL-2	NULL
RECEPTOR	NULL
EXPRESSION	NULL
IN	NULL
HTLV-I-ASSOCIATED	NULL
LEUKEMIA	NULL
anti-Tac	NULL
monoclonal	NULL
antibody	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
patients	NULL
with	NULL
the	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Patient	NULL
Population	NULL
.	NULL

T-cells	NULL
were	NULL
studied	NULL
from	NULL
17	NULL
normal	NULL
individuals	NULL
,	NULL
10	NULL
patients	NULL
with	NULL
the	NULL
Sézary	NULL
leukemia	NULL
who	NULL
did	NULL
not	NULL
have	NULL
antibodies	NULL
to	NULL
HTLV-I	NULL
,	NULL
11	NULL
patients	NULL
with	NULL
the	NULL
ATL	NULL
,	NULL
5	NULL
patients	NULL
with	NULL
acute	NULL
T-cell	NULL
leukemia	NULL
,	NULL
and	NULL
the	NULL
lines	NULL
CCRF-CEM	NULL
,	NULL
Molt-4	NULL
,	NULL
RPMI-8402T	NULL
,	NULL
and	NULL
CCRF-HSB-2	NULL
derived	NULL
from	NULL
patients	NULL
with	NULL
acute	NULL
T-cell	NULL
leukemia	NULL
(	NULL
13	NULL
)	NULL
.	NULL

The	NULL
patients	NULL
with	NULL
the	NULL
diagnosis	NULL
of	NULL
the	NULL
Sézary	NULL
syndrome	NULL
presented	NULL
with	NULL
exfoliative	NULL
erythro-derma	NULL
,	NULL
lymphadenopathy	NULL
,	NULL
and	NULL
a	NULL
white	NULL
blood	NULL
count	NULL
ranging	NULL
from	NULL
12,600	NULL
to	NULL
124,000	NULL
cells/mm	NULL
?	NULL

®	NULL
.	NULL

The	NULL
patients	NULL
with	NULL
ATL	NULL
had	NULL
skin	NULL
involvement	NULL
usually	NULL
in	NULL
the	NULL
form	NULL
of	NULL
plaque-like	NULL
lesions	NULL
and	NULL
had	NULL
white	NULL
blood	NULL
counts	NULL
ranging	NULL
from	NULL
11,200	NULL
to	NULL
105,000/mm*	NULL
.	NULL

Six	NULL
of	NULL
the	NULL
patients	NULL
were	NULL
hyper-calcemic	NULL
.	NULL

Each	NULL
of	NULL
the	NULL
patients	NULL
with	NULL
ATL	NULL
had	NULL
serum	NULL
antibodies	NULL
to	NULL
the	NULL
M	NULL
,	NULL
19,000	NULL
core	NULL
protein	NULL
of	NULL
HTLV-I	NULL
and	NULL
had	NULL
incorporated	NULL
this	NULL
virus	NULL
into	NULL
the	NULL
genome	NULL
of	NULL
the	NULL
leukemic	NULL
cells	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Immunofluorescence	NULL
Analysis	NULL
of	NULL
Cells	NULL
with	NULL
Fluorescence-activated	NULL
Cell	NULL
Sorter	NULL
.	NULL

Peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
were	NULL
analyzed	NULL
using	NULL
immunofluorescence	NULL
and	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
analysis	NULL
by	NULL
a	NULL
slight	NULL
modification	NULL
of	NULL
a	NULL
procedure	NULL
described	NULL
previously	NULL
(	NULL
15	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
of	NULL
patients	NULL
who	NULL
were	NULL
not	NULL
being	NULL
treated	NULL
with	NULL
the	NULL
monoclonal	NULL
antibody	NULL
were	NULL
analyzed	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
using	NULL
anti-Tac	NULL
and	NULL
7G7	NULL
,	NULL
antibodies	NULL
to	NULL
different	NULL
epitopes	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
;	NULL
3A-1	NULL
,	NULL
an	NULL
antibody	NULL
to	NULL
an	NULL
antigen	NULL
expressed	NULL
on	NULL
normal	NULL
T-cells	NULL
but	NULL
not	NULL
on	NULL
Sézary	NULL
or	NULL
adult	NULL
T-cell	NULL
leukemic	NULL
cells	NULL
(	NULL
16	NULL
)	NULL
,	NULL
and	NULL
the	NULL
T4	NULL
,	NULL
T8	NULL
,	NULL
and	NULL
T9	NULL
antibodies	NULL
(	NULL
Ortho	NULL
Pharmaceuticals	NULL
,	NULL
Raritan	NULL
,	NULL
NJ	NULL
)	NULL
and	NULL
the	NULL
Leu	NULL
4	NULL
antibody	NULL
(	NULL
Becton-Dickenson	NULL
&	NULL
Co.	NULL
,	NULL
Sunnyvale	NULL
,	NULL
CA	NULL
)	NULL
as	NULL
the	NULL
first	NULL
antibody	NULL
and	NULL
FITC-conjugated	NULL
goat	NULL
anti-mouse	NULL
immunoglobulin	NULL
(	NULL
Coulter	NULL
Electronics	NULL
,	NULL
Hi-aleah	NULL
,	NULL
FL	NULL
)	NULL
as	NULL
the	NULL
second	NULL
antibody	NULL
.	NULL

Following	NULL
therapy	NULL
with	NULL
anti-Tac	NULL
,	NULL
the	NULL
T-cells	NULL
of	NULL
the	NULL
patients	NULL
were	NULL
analyzed	NULL
by	NULL
direct	NULL
immunofluorescence	NULL
using	NULL
FITC	NULL
conjugates	NULL
of	NULL
goat	NULL
anti-mouse	NULL
immunoglobulin	NULL
,	NULL
anti-	NULL
Tac	NULL
,	NULL
7G7	NULL
,	NULL
3A-1	NULL
,	NULL
T9	NULL
,	NULL
and	NULL
Leu	NULL
4	NULL
.	NULL

FITC-conjugated	NULL
goat	NULL
IgG	NULL
was	NULL
used	NULL
as	NULL
the	NULL
negative	NULL
control	NULL
.	NULL

Determination	NULL
of	NULL
TG	NULL
Gene	NULL
Configuration	NULL
.	NULL

The	NULL
arrangement	NULL
of	NULL
the	NULL
TB	NULL
genes	NULL
in	NULL
the	NULL
leukemic	NULL
T-ceils	NULL
of	NULL
a	NULL
patient	NULL
with	NULL
ATL	NULL
at	NULL
various	NULL
periods	NULL
prior	NULL
to	NULL
and	NULL
following	NULL
therapy	NULL
with	NULL
anti-T	NULL
ac	NULL
was	NULL
analyzed	NULL
and	NULL
compared	NULL
to	NULL
the	NULL
arrangement	NULL
of	NULL
these	NULL
genes	NULL
in	NULL
peripheral	NULL
blood	NULL
buffy	NULL
coat	NULL
cells	NULL
of	NULL
normal	NULL
individuals	NULL
,	NULL
and	NULL
in	NULL
a	NULL
B-cell	NULL
line	NULL
that	NULL
was	NULL
established	NULL
from	NULL
the	NULL
patient	NULL
using	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

High	NULL
molecular	NULL
weight	NULL
DNA	NULL
was	NULL
extracted	NULL
from	NULL
the	NULL
leukemic	NULL
and	NULL
normal	NULL
cells	NULL
and	NULL
was	NULL
digested	NULL
to	NULL
completion	NULL
with	NULL
BamHI	NULL
,	NULL
size	NULL
fractionated	NULL
over	NULL
agarose	NULL
gels	NULL
by	NULL
electro-phoresis	NULL
,	NULL
and	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
paper	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
.	NULL

Such	NULL
paper-bound	NULL
DNA	NULL
fragments	NULL
were	NULL
then	NULL
hybridized	NULL
to	NULL
a	NULL
random	NULL
primed	NULL
[	NULL
°PJDNA	NULL
probe	NULL
to	NULL
the	NULL
constant	NULL
domain	NULL
of	NULL
the	NULL
TB	NULL
gene	NULL
(	NULL
19	NULL
)	NULL
obtained	NULL
from	NULL
Mark	NULL
Davis	NULL
.	NULL

After	NULL
washes	NULL
at	NULL
the	NULL
appropriate	NULL
stringency	NULL
,	NULL
the	NULL
TB	NULL
gene	NULL
configurations	NULL
were	NULL
visualized	NULL
on	NULL
autoradiograms	NULL
.	NULL

Results	NULL
and	NULL
Discussion	NULL
IL-2	NULL
Receptor	NULL
Expression	NULL
in	NULL
Adult	NULL
T-Cell	NULL
Leukemia	NULL
.	NULL

Peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
three	NULL
forms	NULL
of	NULL
T-cell	NULL
leukemia-acute	NULL
T-cell	NULL
leukemia	NULL
,	NULL
the	NULL
Sézary	NULL
leukemia	NULL
,	NULL
and	NULL
adult	NULL
T-cell	NULL
leukemia-were	NULL
analyzed	NULL
for	NULL
IL-2	NULL
receptor	NULL
expression	NULL
using	NULL
indirect	NULL
immunofluorescence	NULL
using	NULL
the	NULL
anti-Tac	NULL
monoclonal	NULL
antibody	NULL
.	NULL

The	NULL
acute	NULL
T-cell	NULL
leukemic	NULL
populations	NULL
and	NULL
lines	NULL
derived	NULL
from	NULL
such	NULL
cells	NULL
did	NULL
not	NULL
express	NULL
IL-2	NULL
receptors	NULL
.	NULL

Furthermore	NULL
,	NULL
nine	NULL
of	NULL
the	NULL
ten	NULL
populations	NULL
of	NULL
Sézary	NULL
leukemic	NULL
T-cells	NULL
not	NULL
associated	NULL
with	NULL
HTLV-I	NULL
examined	NULL
were	NULL
Tac	NULL
antigen	NULL
negative	NULL
(	NULL
13	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
all	NULL
of	NULL
the	NULL
populations	NULL
of	NULL
leukemic	NULL
cells	NULL
from	NULL
the	NULL
11	NULL
patients	NULL
studied	NULL
with	NULL
the	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
associated	NULL
with	NULL
HTLV-I	NULL
expressed	NULL
the	NULL
Tac	NULL
antigen	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
demonstration	NULL
of	NULL
IL-2	NULL
receptors	NULL
on	NULL
leukemic	NULL
T-cells	NULL
may	NULL
aid	NULL
in	NULL
differentiating	NULL
those	NULL
leukemias	NULL
caused	NULL
by	NULL
HTLV-I	NULL
,	NULL
which	NULL
are	NULL
Tac	NULL
antigen	NULL
positive	NULL
,	NULL
from	NULL
other	NULL
forms	NULL
of	NULL
T-cell	NULL
leukemia	NULL
which	NULL
are	NULL
,	NULL
in	NULL
general	NULL
,	NULL
Tac	NULL
antigen	NULL
negative	NULL
.	NULL

The	NULL
IL-2	NULL
receptor	NULL
expression	NULL
on	NULL
adult	NULL
T-cell	NULL
leukemic	NULL
cells	NULL
differed	NULL
from	NULL
that	NULL
on	NULL
normal	NULL
T-cells	NULL
.	NULL

First	NULL
,	NULL
unlike	NULL
normal	NULL
T-cells	NULL
,	NULL
ATL	NULL
cells	NULL
do	NULL
not	NULL
require	NULL
prior	NULL
activation	NULL
to	NULL
express	NULL
the	NULL
IL-2	NULL
receptors	NULL
.	NULL

Furthermore	NULL
,	NULL
using	NULL
a	NULL
°H-labeled	NULL
anti-Tac	NULL
receptor	NULL
assay	NULL
,	NULL
HTLV-I	NULL
infected	NULL
leukemic	NULL
T-cell	NULL
lines	NULL
characteristically	NULL
expressed	NULL
5-	NULL
to	NULL
10-fold	NULL
more	NULL
receptors	NULL
per	NULL
cell	NULL
(	NULL
270,000	NULL
to	NULL
640,000	NULL
)	NULL
than	NULL
did	NULL
maximally	NULL
PHA-stimulated	NULL
T-lymphoblasts	NULL
(	NULL
30,000	NULL
to	NULL
60,000	NULL
)	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
cell	NULL
volume	NULL
of	NULL
these	NULL
leukemic	NULL
cells	NULL
was	NULL
only	NULL
13	NULL
%	NULL
greater	NULL
than	NULL
that	NULL
of	NULL
PHA	NULL
lymphoblasts	NULL
,	NULL
the	NULL
density	NULL
of	NULL
IL-2	NULL
receptors	NULL
on	NULL
these	NULL
leukemic	NULL
cells	NULL
was	NULL
correspondingly	NULL
increased	NULL
.	NULL

in	NULL
addition	NULL
,	NULL
whereas	NULL
normal	NULL
PHA-stimulated	NULL
human	NULL
T-lymphocytes	NULL
maintained	NULL
in	NULL
culture	NULL
with	NULL
IL-2	NULL
demonstrated	NULL
a	NULL
rapid	NULL
decline	NULL
in	NULL
receptor	NULL
number	NULL
from	NULL
a	NULL
maximum	NULL
of	NULL
20,000	NULL
receptors	NULL
per	NULL
cell	NULL
on	NULL
Day	NULL
3	NULL
to	NULL
approximately	NULL
5,000	NULL
on	NULL
Day	NULL
13	NULL
,	NULL
the	NULL
ATL	NULL
lines	NULL
did	NULL
not	NULL
show	NULL
a	NULL
similar	NULL
decline	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
have	NULL
noted	NULL
that	NULL
some	NULL
,	NULL
but	NULL
not	NULL
all	NULL
,	NULL
HTLV-I	NULL
infected	NULL
continuous	NULL
T-cell	NULL
lines	NULL
display	NULL
aberrantly	NULL
sized	NULL
IL-2	NULL
receptors	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

For	NULL
example	NULL
,	NULL
the	NULL
receptor	NULL
on	NULL
HTLV-I	NULL
infected	NULL
HUT	NULL
102-B2	NULL
cells	NULL
is	NULL
approximately	NULL
5,000	NULL
daltons	NULL
smaller	NULL
than	NULL
that	NULL
on	NULL
PHA	NULL
lympho-blasts	NULL
.	NULL

Using	NULL
pulse	NULL
chase	NULL
,	NULL
tunicamycin	NULL
,	NULL
endoglycosidase	NULL
,	NULL
and	NULL
neuraminidase	NULL
analyses	NULL
,	NULL
the	NULL
difference	NULL
in	NULL
receptor	NULL
size	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
due	NULL
to	NULL
differences	NULL
in	NULL
posttranslational	NULL
modification	NULL
of	NULL
the	NULL
M	NULL
,	NULL
33,000	NULL
protein	NULL
backbone	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
receptors	NULL
on	NULL
the	NULL
HUT	NULL
102-B2	NULL
cells	NULL
manifested	NULL
less	NULL
sulfation	NULL
than	NULL
did	NULL
normal	NULL
receptors	NULL
.	NULL

Finally	NULL
,	NULL
Uchiyama	NULL
and	NULL
coworkers	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
have	NULL
reported	NULL
that	NULL
IL-2	NULL
receptors	NULL
on	NULL
ATL	NULL
cells	NULL
are	NULL
not	NULL
modulated	NULL
(	NULL
down-regulated	NULL
)	NULL
by	NULL
anti-Tac	NULL
(	NULL
unlike	NULL
normal	NULL
activated	NULL
T-cells	NULL
)	NULL
and	NULL
that	NULL
IL-2	NULL
receptors	NULL
on	NULL
ATL	NULL
cell	NULL
lines	NULL
were	NULL
spontaneously	NULL
(	NULL
IL-2	NULL
independently	NULL
)	NULL
phosphorylated	NULL
,	NULL
whereas	NULL
the	NULL
phosphorylation	NULL
of	NULL
receptors	NULL
on	NULL
PHA-stimulated	NULL
T-cells	NULL
requires	NULL
the	NULL
addition	NULL
of	NULL
IL-2	NULL
.	NULL

it	NULL
is	NULL
conceivable	NULL
that	NULL
the	NULL
constant	NULL
presence	NULL
of	NULL
high	NULL
numbers	NULL
of	NULL
IL-2	NULL
receptors	NULL
on	NULL
the	NULL
adult	NULL
T-cell	NULL
leukemic	NULL
cells	NULL
and/or	NULL
the	NULL
aberrancy	NULL
of	NULL
these	NULL
receptors	NULL
may	NULL
play	NULL
a	NULL
major	NULL
role	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
uncontrolled	NULL
growth	NULL
of	NULL
these	NULL
malignant	NULL
T-cells	NULL
.	NULL

As	NULL
noted	NULL
above	NULL
,	NULL
the	NULL
T-cell	NULL
leukemias	NULL
caused	NULL
by	NULL
HTLV-I	NULL
express	NULL
the	NULL
Tac	NULL
antigen	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
all	NULL
T-cell	NULL
and	NULL
the	NULL
five	NULL
B-cell	NULL
lines	NULL
we	NULL
examined	NULL
that	NULL
were	NULL
infected	NULL
with	NULL
HTLV-I	NULL
universally	NULL
expressed	NULL
large	NULL
numbers	NULL
of	NULL
IL-2	NULL
receptors	NULL
.	NULL

A	NULL
recent	NULL
report	NULL
by	NULL
Sodorski	NULL
et	NULL
al	NULL
.	NULL

(	NULL
25	NULL
)	NULL
suggests	NULL
a	NULL
potential	NULL
mechanism	NULL
for	NULL
this	NULL
association	NULL
between	NULL
HTLV-I	NULL
and	NULL
IL-2	NULL
receptor	NULL
expression	NULL
.	NULL

The	NULL
complete	NULL
sequence	NULL
of	NULL
HTLV-I	NULL
has	NULL
been	NULL
determined	NULL
by	NULL
Seiki	NULL
et	NULL
al	NULL
.	NULL

(	NULL
26	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
gag	NULL
,	NULL
pol	NULL
,	NULL
env	NULL
,	NULL
and	NULL
LTR	NULL
sequences	NULL
common	NULL
to	NULL
other	NULL
groups	NULL
of	NULL
retroviruses	NULL
,	NULL
HTLV-I	NULL
was	NULL
shown	NULL
to	NULL
contain	NULL
an	NULL
additional	NULL
genomic	NULL
region	NULL
between	NULL
env	NULL
and	NULL
the	NULL
LTR	NULL
referred	NULL
to	NULL
as	NULL
pX	NULL
.	NULL

Sodorski	NULL
et	NULL
al	NULL
.	NULL

(	NULL
25	NULL
)	NULL
demonstrated	NULL
that	NULL
a	NULL
M	NULL
,	NULL
38,000	NULL
to	NULL
42,000	NULL
protein	NULL
termed	NULL
LOR	NULL
is	NULL
encoded	NULL
,	NULL
in	NULL
large	NULL
measure	NULL
,	NULL
by	NULL
the	NULL
3	NULL
'	NULL
1000	NULL
bases	NULL
of	NULL
the	NULL
pX	NULL
region	NULL
and	NULL
that	NULL
this	NULL
LOR	NULL
protein	NULL
may	NULL
act	NULL
as	NULL
a	NULL
transacting	NULL
regulator	NULL
of	NULL
transcription	NULL
.	NULL

They	NULL
demonstrated	NULL
that	NULL
the	NULL
LOR	NULL
protein	NULL
acts	NULL
on	NULL
regulatory	NULL
sequences	NULL
in	NULL
the	NULL
LTRs	NULL
of	NULL
HTLV-I	NULL
,	NULL
-II	NULL
,	NULL
and	NULL
-llI	NULL
stimulating	NULL
transcription	NULL
.	NULL

The	NULL
LOR	NULL
protein	NULL
could	NULL
theoretically	NULL
also	NULL
play	NULL
a	NULL
central	NULL
role	NULL
in	NULL
increasing	NULL
the	NULL
transcription	NULL
of	NULL
host	NULL
genes	NULL
such	NULL
as	NULL
the	NULL
IL-2	NULL
receptor	NULL
gene	NULL
involved	NULL
in	NULL
T-cell	NULL
activation	NULL
and	NULL
HTLV-l-mediated	NULL
leukemogenesis	NULL
.	NULL

With	NULL
the	NULL
cloning	NULL
of	NULL
the	NULL
gene	NULL
encoding	NULL
the	NULL
IL-2	NULL
receptor	NULL
(	NULL
27	NULL
)	NULL
,	NULL
this	NULL
hypothesis	NULL
that	NULL
the	NULL
LOR	NULL
protein	NULL
acts	NULL
as	NULL
a	NULL
transacting	NULL
regulator	NULL
of	NULL
transcription	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
gene	NULL
can	NULL
now	NULL
be	NULL
readily	NULL
tested	NULL
.	NULL

CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

45	NULL
SEPTEMBER	NULL
1985	NULL
4560s	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1985	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

IL-2	NULL
RECEPTOR	NULL
EXPRESSION	NULL
IN	NULL
HTLV-I-ASSOCIATED	NULL
LEUKEMIA	NULL
Treatment	NULL
of	NULL
Patients	NULL
with	NULL
Adult	NULL
T-Cell	NULL
Leukemia	NULL
with	NULL
the	NULL
Anti-Tac	NULL
Monoconal	NULL
Antibody	NULL
.	NULL

We	NULL
have	NULL
initiated	NULL
a	NULL
clinical	NULL
trial	NULL
to	NULL
evaluate	NULL
the	NULL
efficacy	NULL
of	NULL
i.v	NULL
.	NULL

administered	NULL
anti-T	NULL
ac	NULL
monoclonal	NULL
antibody	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
patients	NULL
with	NULL
the	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
.	NULL

The	NULL
scientific	NULL
basis	NULL
for	NULL
these	NULL
studies	NULL
is	NULL
the	NULL
observation	NULL
that	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
cells	NULL
express	NULL
the	NULL
Tac	NULL
antigen	NULL
,	NULL
whereas	NULL
normal	NULL
resting	NULL
T-cells	NULL
and	NULL
their	NULL
precursors	NULL
do	NULL
not	NULL
.	NULL

Two	NULL
patients	NULL
with	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
have	NULL
been	NULL
treated	NULL
with	NULL
i.v	NULL
.	NULL

administered	NULL
anti-Tac	NULL
.	NULL

Neither	NULL
patient	NULL
suffered	NULL
any	NULL
untoward	NULL
reactions	NULL
nor	NULL
did	NULL
they	NULL
produce	NULL
antibodies	NULL
reactive	NULL
with	NULL
mouse	NULL
immunoglobulin	NULL
or	NULL
the	NULL
idiotype	NULL
of	NULL
the	NULL
anti-Tac	NULL
monoclonal	NULL
.	NULL

One	NULL
patient	NULL
with	NULL
a	NULL
very	NULL
rapidly	NULL
developing	NULL
form	NULL
of	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
had	NULL
a	NULL
very	NULL
transient	NULL
response	NULL
.	NULL

However	NULL
,	NULL
therapy	NULL
of	NULL
the	NULL
other	NULL
patient	NULL
was	NULL
followed	NULL
by	NULL
a	NULL
6-mo	NULL
remission	NULL
as	NULL
assessed	NULL
by	NULL
regression	NULL
of	NULL
skin	NULL
lesions	NULL
,	NULL
routine	NULL
hematological	NULL
tests	NULL
,	NULL
immunofiluorescence	NULL
analysis	NULL
,	NULL
and	NULL
molecular	NULL
genetic	NULL
analysis	NULL
of	NULL
the	NULL
arrangement	NULL
of	NULL
T-cell	NULL
receptor	NULL
8	NULL
chain	NULL
genes	NULL
.	NULL

The	NULL
patient	NULL
,	NULL
a	NULL
24-yr-old	NULL
black	NULL
man	NULL
,	NULL
developed	NULL
cryptococcal	NULL
meningitis	NULL
and	NULL
papular	NULL
neoplastic	NULL
skin	NULL
lesions	NULL
that	NULL
showed	NULL
diffuse	NULL
mixed	NULL
lymphoma	NULL
on	NULL
histological	NULL
examination	NULL
.	NULL

The	NULL
patient	NULL
was	NULL
treated	NULL
with	NULL
nine	NULL
cycles	NULL
of	NULL
ProMACE-MOPP	NULL
chemotherapy	NULL
and	NULL
had	NULL
a	NULL
complete	NULL
remission	NULL
lasting	NULL
26	NULL
mo	NULL
.	NULL

He	NULL
relapsed	NULL
with	NULL
recurrent	NULL
papular	NULL
adenopathy	NULL
,	NULL
hypercalcemia	NULL
,	NULL
and	NULL
a	NULL
peripheral	NULL
blood	NULL
WBC	NULL
count	NULL
of	NULL
26,800/	NULL
mm	NULL
.	NULL

He	NULL
achieved	NULL
a	NULL
second	NULL
complete	NULL
remission	NULL
on	NULL
Pro-MACE-MOPP	NULL
chemotherapy	NULL
and	NULL
had	NULL
a	NULL
series	NULL
of	NULL
remissions	NULL
and	NULL
re-lapses	NULL
.	NULL

Five	NULL
mo	NULL
after	NULL
the	NULL
last	NULL
course	NULL
of	NULL
ProMACE-MOPP	NULL
chem-otherapy	NULL
,	NULL
the	NULL
patient	NULL
had	NULL
a	NULL
relapse	NULL
with	NULL
2,200	NULL
malignant	NULL
T-cells/	NULL
mm	NULL
?	NULL

in	NULL
the	NULL
circulation	NULL
as	NULL
assessed	NULL
by	NULL
immunofluorescence	NULL
analysis	NULL
using	NULL
the	NULL
anti-Tac	NULL
monoclonal	NULL
antibody	NULL
.	NULL

Furthermore	NULL
,	NULL
1,200	NULL
of	NULL
these	NULL
circulating	NULL
Iymphocytes/mm®	NULL
reacted	NULL
with	NULL
T9	NULL
,	NULL
an	NULL
antibody	NULL
to	NULL
the	NULL
transferrin	NULL
receptor	NULL
,	NULL
which	NULL
is	NULL
a	NULL
receptor	NULL
expressed	NULL
on	NULL
the	NULL
malignant	NULL
but	NULL
not	NULL
on	NULL
normal	NULL
circulating	NULL
T-cells	NULL
.	NULL

The	NULL
patient	NULL
was	NULL
then	NULL
treated	NULL
with	NULL
three	NULL
i.v	NULL
.	NULL

infusions	NULL
(	NULL
20	NULL
,	NULL
40	NULL
,	NULL
and	NULL
40	NULL
mg	NULL
)	NULL
of	NULL
the	NULL
anti-Tac	NULL
monoclonal	NULL
antibody	NULL
over	NULL
a	NULL
10-day	NULL
period	NULL
.	NULL

Following	NULL
the	NULL
anti-T	NULL
ac	NULL
therapy	NULL
,	NULL
there	NULL
was	NULL
a	NULL
decline	NULL
in	NULL
the	NULL
number	NULL
of	NULL
circulating	NULL
T-cells	NULL
bearing	NULL
the	NULL
Tac	NULL
antigen	NULL
from	NULL
2,200	NULL
to	NULL
less	NULL
than	NULL
100/mm*	NULL
and	NULL
of	NULL
transferrin	NULL
receptor	NULL
expressing	NULL
T-cells	NULL
from	NULL
1,200	NULL
to	NULL
less	NULL
than	NULL
100/mm®	NULL
.	NULL

During	NULL
the	NULL
4-wk	NULL
period	NULL
following	NULL
the	NULL
anti-T	NULL
ac	NULL
infusions	NULL
,	NULL
there	NULL
were	NULL
no	NULL
cells	NULL
with	NULL
free	NULL
IL-2	NULL
receptors	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
with	NULL
receptors	NULL
unblocked	NULL
by	NULL
the	NULL
infused	NULL
anti-Tac	NULL
monoclonal	NULL
,	NULL
whereas	NULL
small	NULL
numbers	NULL
of	NULL
circulating	NULL
cells	NULL
with	NULL
anti-Tac	NULL
blocking	NULL
the	NULL
IL-2	NULL
receptor	NULL
were	NULL
identified	NULL
.	NULL

Cells	NULL
with	NULL
blocked	NULL
IL-2	NULL
receptors	NULL
were	NULL
identified	NULL
as	NULL
cells	NULL
that	NULL
were	NULL
not	NULL
reactive	NULL
with	NULL
FITC-conjugated	NULL
anti-Tac	NULL
but	NULL
were	NULL
reactive	NULL
with	NULL
FITC-conjugated	NULL
anti-mouse	NULL
IgG	NULL
and	NULL
with	NULL
the	NULL
7G7	NULL
monoclonal	NULL
antibody	NULL
,	NULL
an	NULL
antibody	NULL
that	NULL
identifies	NULL
an	NULL
epitope	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
peptide	NULL
other	NULL
than	NULL
that	NULL
identified	NULL
by	NULL
anti-Tac	NULL
.	NULL

The	NULL
remission	NULL
of	NULL
the	NULL
T-cell	NULL
leukemia	NULL
in	NULL
this	NULL
patient	NULL
was	NULL
confirmed	NULL
utilizing	NULL
molecular	NULL
genetic	NULL
analysis	NULL
of	NULL
the	NULL
arrangement	NULL
of	NULL
the	NULL
genes	NULL
encoding	NULL
the	NULL
8	NULL
chain	NULL
of	NULL
the	NULL
antigen-specific	NULL
T-cell	NULL
receptor	NULL
.	NULL

Southern	NULL
analysis	NULL
of	NULL
the	NULL
arrangement	NULL
of	NULL
the	NULL
T-cell	NULL
receptor	NULL
B	NULL
chain	NULL
gene	NULL
was	NULL
performed	NULL
on	NULL
BamHI	NULL
digests	NULL
of	NULL
DNA	NULL
from	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
of	NULL
the	NULL
patient	NULL
using	NULL
a	NULL
radiolabeled	NULL
probe	NULL
to	NULL
the	NULL
constant	NULL
region	NULL
of	NULL
the	NULL
TR	NULL
chain	NULL
.	NULL

The	NULL
constant	NULL
TB	NULL
genes	NULL
were	NULL
universally	NULL
present	NULL
on	NULL
a	NULL
24-kilobase	NULL
BamHI	NULL
fragment	NULL
in	NULL
germ-line	NULL
tissues	NULL
of	NULL
normal	NULL
individuals	NULL
and	NULL
in	NULL
a	NULL
B-cell	NULL
line	NULL
derived	NULL
from	NULL
the	NULL
patient	NULL
.	NULL

However	NULL
,	NULL
prior	NULL
to	NULL
therapy	NULL
,	NULL
there	NULL
was	NULL
an	NULL
additional	NULL
22-kilobase	NULL
BamHI	NULL
band	NULL
hybridizing	NULL
with	NULL
the	NULL
constant	NULL
T	NULL
,	NULL
probe	NULL
when	NULL
digests	NULL
of	NULL
the	NULL
patient	NULL
's	NULL
circulating	NULL
T-cells	NULL
were	NULL
examined	NULL
,	NULL
a	NULL
hallmark	NULL
of	NULL
a	NULL
clonal	NULL
expansion	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

This	NULL
band	NULL
reflecting	NULL
the	NULL
clonally	NULL
rearranged	NULL
T-cell	NULL
receptor	NULL
gene	NULL
was	NULL
not	NULL
demonstrable	NULL
on	NULL
specimens	NULL
obtained	NULL
following	NULL
anti-Tac	NULL
therapy	NULL
when	NULL
the	NULL
patient	NULL
was	NULL
in	NULL
remission	NULL
.	NULL

Six	NULL
mo	NULL
following	NULL
the	NULL
initial	NULL
remission	NULL
,	NULL
the	NULL
leukemia	NULL
recurred	NULL
with	NULL
a	NULL
reappearance	NULL
of	NULL
circulating	NULL
leukemic	NULL
cells	NULL
,	NULL
identified	NULL
by	NULL
immunofluorescence	NULL
and	NULL
molecular	NULL
genetic	NULL
analysis	NULL
,	NULL
and	NULL
with	NULL
the	NULL
development	NULL
of	NULL
large	NULL
(	NULL
5	NULL
x	NULL
7	NULL
x	NULL
1	NULL
cm	NULL
)	NULL
malignant	NULL
skin	NULL
lesions	NULL
.	NULL

A	NULL
second	NULL
course	NULL
of	NULL
three	NULL
i.v	NULL
.	NULL

infusions	NULL
of	NULL
20	NULL
mg	NULL
each	NULL
of	NULL
anti-Tac	NULL
over	NULL
a	NULL
10-day	NULL
period	NULL
was	NULL
followed	NULL
by	NULL
the	NULL
virtual	NULL
disappearance	NULL
of	NULL
the	NULL
skin	NULL
lesions	NULL
and	NULL
an	NULL
over	NULL
90	NULL
%	NULL
reduction	NULL
in	NULL
the	NULL
number	NULL
of	NULL
circulating	NULL
leukemic	NULL
cells	NULL
.	NULL

Three	NULL
mo	NULL
subsequently	NULL
leukemic	NULL
cells	NULL
were	NULL
again	NULL
demonstrable	NULL
in	NULL
the	NULL
circulation	NULL
.	NULL

At	NULL
this	NULL
time	NULL
the	NULL
leukemia	NULL
was	NULL
no	NULL
longer	NULL
responsive	NULL
to	NULL
infusions	NULL
of	NULL
anti-T	NULL
ac	NULL
,	NULL
and	NULL
the	NULL
patient	NULL
required	NULL
further	NULL
chemotherapy	NULL
.	NULL

There	NULL
was	NULL
no	NULL
toxicity	NULL
associated	NULL
with	NULL
the	NULL
anti-T	NULL
ac	NULL
therapy	NULL
nor	NULL
was	NULL
there	NULL
a	NULL
reduction	NULL
in	NULL
the	NULL
number	NULL
of	NULL
any	NULL
of	NULL
the	NULL
normal	NULL
formed	NULL
elements	NULL
of	NULL
the	NULL
blood	NULL
including	NULL
normal	NULL
T-cells	NULL
.	NULL

Normal	NULL
T-cells	NULL
could	NULL
be	NULL
identified	NULL
by	NULL
immunofluorescence	NULL
analysis	NULL
,	NULL
since	NULL
they	NULL
expressed	NULL
the	NULL
antigen	NULL
defined	NULL
by	NULL
the	NULL
3A-1	NULL
monoclonal	NULL
antibody	NULL
,	NULL
whereas	NULL
the	NULL
leukemic	NULL
cells	NULL
did	NULL
not	NULL
express	NULL
this	NULL
antigen	NULL
.	NULL

The	NULL
patient	NULL
did	NULL
not	NULL
produce	NULL
antibodies	NULL
to	NULL
mouse	NULL
IgG	NULL
nor	NULL
to	NULL
the	NULL
idiotype	NULL
of	NULL
anti-T	NULL
ac	NULL
as	NULL
assessed	NULL
using	NULL
an	NULL
enzyme-linked	NULL
immu-nosorbent	NULL
assay	NULL
procedure	NULL
.	NULL

These	NULL
therapeutic	NULL
studies	NULL
have	NULL
been	NULL
extended	NULL
in	NULL
vitro	NULL
by	NULL
examining	NULL
the	NULL
efficacy	NULL
of	NULL
toxins	NULL
coupled	NULL
to	NULL
anti-T	NULL
ac	NULL
in	NULL
selectively	NULL
inhibiting	NULL
the	NULL
protein	NULL
synthesis	NULL
and	NULL
the	NULL
viability	NULL
of	NULL
Tac-positive	NULL
adult	NULL
T-cell	NULL
leukemic	NULL
cell	NULL
lines	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
anti-T	NULL
ac	NULL
antibody	NULL
coupled	NULL
to	NULL
the	NULL
A	NULL
chain	NULL
of	NULL
the	NULL
toxin	NULL
ricin	NULL
effectively	NULL
inhibited	NULL
protein	NULL
synthesis	NULL
by	NULL
the	NULL
HTLV-l-associated	NULL
,	NULL
Tac-positive	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
line	NULL
HUT	NULL
102-B2	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
conjugates	NULL
of	NULL
ricin	NULL
A	NULL
with	NULL
a	NULL
control	NULL
monocional	NULL
of	NULL
the	NULL
same	NULL
isotype	NULL
did	NULL
not	NULL
inhibit	NULL
protein	NULL
synthesis	NULL
when	NULL
used	NULL
in	NULL
the	NULL
same	NULL
concentration	NULL
(	NULL
107°	NULL
m	NULL
)	NULL
(	NULL
28	NULL
)	NULL
.	NULL

The	NULL
inhibitory	NULL
action	NULL
of	NULL
anti-Tac	NULL
conjugated	NULL
with	NULL
ricin	NULL
A	NULL
could	NULL
be	NULL
abolished	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
excess	NULL
unlabeled	NULL
anti-Tac	NULL
or	NULL
IL-2	NULL
.	NULL

In	NULL
parallel	NULL
studies	NULL
performed	NULL
in	NULL
collaboration	NULL
with	NULL
D.	NULL
FitzGerald	NULL
et	NULL
a/	NULL
.	NULL

(	NULL
29	NULL
)	NULL
,	NULL
Pseudomonas	NULL
exotoxin	NULL
conjugates	NULL
of	NULL
anti-Tac	NULL
inhibited	NULL
the	NULL
protein	NULL
synthesis	NULL
by	NULL
HUT	NULL
102-B2	NULL
cells	NULL
but	NULL
not	NULL
that	NULL
of	NULL
the	NULL
acute	NULL
T-cell	NULL
leukemia	NULL
line	NULL
Molt-4	NULL
that	NULL
does	NULL
not	NULL
express	NULL
the	NULL
Tac	NULL
antigen	NULL
.	NULL

Again	NULL
,	NULL
the	NULL
toxicity	NULL
of	NULL
the	NULL
anti-Tac	NULL
toxin	NULL
conjugates	NULL
could	NULL
be	NULL
inhibited	NULL
by	NULL
adding	NULL
excess	NULL
unlabeled	NULL
anti-T	NULL
ac	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
development	NULL
of	NULL
toxin	NULL
conjugates	NULL
of	NULL
the	NULL
monoclonal	NULL
anti-T	NULL
ac	NULL
that	NULL
is	NULL
directed	NULL
toward	NULL
the	NULL
IL-2	NULL
receptor	NULL
expressed	NULL
on	NULL
adult	NULL
T-cell	NULL
leukemic	NULL
cells	NULL
may	NULL
permit	NULL
the	NULL
development	NULL
of	NULL
a	NULL
rational	NULL
approach	NULL
for	NULL
the	NULL
treatment	NULL
of	NULL
this	NULL
almost	NULL
uniformly	NULL
fatal	NULL
form	NULL
of	NULL
leukemia	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Allison	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Mcintyre	NULL
,	NULL
B.	NULL
W.	NULL
,	NULL
and	NULL
Bloch	NULL
,	NULL
D.	NULL
Tumor-specific	NULL
antigen	NULL
of	NULL
murine	NULL
T-lymphoma	NULL
defined	NULL
with	NULL
monoclonal	NULL
antibody	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
129	NULL
;	NULL
2293-2300	NULL
,	NULL
1982	NULL
.	NULL

2	NULL
.	NULL

Haskins	NULL
,	NULL
K.	NULL
,	NULL
Kubo	NULL
,	NULL
R.	NULL
,	NULL
White	NULL
,	NULL
J.	NULL
,	NULL
Pigeon	NULL
,	NULL
M.	NULL
,	NULL
Kappler	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Marrack	NULL
,	NULL
P.	NULL
The	NULL
major	NULL
histocompatibility	NULL
complex-restricted	NULL
antigen	NULL
receptor	NULL
on	NULL
T	NULL
cells	NULL
.	NULL

isolation	NULL
with	NULL
a	NULL
monoclonal	NULL
antibody	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
157	NULL
:	NULL
1149-1169	NULL
,	NULL
1983	NULL
.	NULL

3	NULL
.	NULL

Meuer	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Fitzgerald	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Hussey	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Hodgdon	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Schiossman	NULL
,	NULL
S.	NULL
F.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
Clonotypic	NULL
structures	NULL
involved	NULL
in	NULL
antigen-specific	NULL
human	NULL
T-cell	NULL
function	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
157	NULL
:	NULL
705-719	NULL
,	NULL
1983	NULL
.	NULL

4	NULL
.	NULL

Morgan	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Ruscetti	NULL
,	NULL
F.	NULL
W.	NULL
,	NULL
and	NULL
Gallo	NULL
,	NULL
R.	NULL
C.	NULL
Selective	NULL
in	NULL
vitro	NULL
growth	NULL
of	NULL
T	NULL
lymphocytes	NULL
from	NULL
normal	NULL
human	NULL
bone	NULL
marrows	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
,	NULL
193	NULL
;	NULL
1007-1008	NULL
,	NULL
1983	NULL
.	NULL

5	NULL
.	NULL

Smith	NULL
,	NULL
K.	NULL
A.	NULL
T-cell	NULL
growth	NULL
factor	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

,	NULL
51	NULL
:	NULL
337-357	NULL
,	NULL
1980	NULL
.	NULL

6	NULL
.	NULL

Robb	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Munck	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Smith	NULL
,	NULL
K.	NULL
A.	NULL
T-cell	NULL
growth	NULL
factor	NULL
receptors	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
154	NULL
;	NULL
1455-1474	NULL
,	NULL
1981	NULL
.	NULL

7	NULL
.	NULL

Uchiyama	NULL
,	NULL
T.	NULL
,	NULL
Broder	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Waldmann	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

A	NULL
monoclonal	NULL
antibody	NULL
(	NULL
anti-	NULL
CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

45	NULL
SEPTEMBER	NULL
1985	NULL
4561s	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1985	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

IL-2	NULL
RECEPTOR	NULL
EXPRESSION	NULL
IN	NULL
LEUKEMIA	NULL
Tac	NULL
)	NULL
reactive	NULL
with	NULL
activated	NULL
and	NULL
functionally	NULL
mature	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

1	NULL
.	NULL

Production	NULL
of	NULL
anti-Tac	NULL
monocional	NULL
antibody	NULL
and	NULL
distribution	NULL
of	NULL
Tac	NULL
(	NULL
+	NULL
)	NULL
cells	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
126	NULL
:	NULL
1393-1397	NULL
,	NULL
1981.	NULL
.	NULL

Leonard	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Depper	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Uchiyama	NULL
,	NULL
T.	NULL
,	NULL
Smith	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Waldmann	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
A	NULL
monoclonal	NULL
antibody	NULL
that	NULL
appears	NULL
to	NULL
recognize	NULL
the	NULL
receptor	NULL
for	NULL
human	NULL
T-cell	NULL
growth	NULL
factor	NULL
;	NULL
partial	NULL
characterization	NULL
of	NULL
the	NULL
receptor	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
300	NULL
:	NULL
267-269	NULL
,	NULL
1982.	NULL
.	NULL

Leonard	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Depper	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Robb	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Waldmann	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
Characterization	NULL
of	NULL
the	NULL
human	NULL
receptor	NULL
for	NULL
T-cell	NULL
growth	NULL
factor	NULL
.	NULL

Proc	NULL
.	NULL

Nati	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
80	NULL
:	NULL
6957-6961	NULL
,	NULL
1983	NULL
.	NULL

Robb	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
Direct	NULL
demonstration	NULL
of	NULL
the	NULL
identity	NULL
of	NULL
T-cell	NULL
growth	NULL
factor	NULL
binding	NULL
protein	NULL
and	NULL
the	NULL
Tac	NULL
antigen	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
158	NULL
:	NULL
1332-1337	NULL
,	NULL
1983	NULL
.	NULL

Uchiyama	NULL
,	NULL
T.	NULL
,	NULL
Nelson	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Fleisher	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
and	NULL
Waldmann	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

A	NULL
monoclonal	NULL
antibody	NULL
(	NULL
anti-Tac	NULL
)	NULL
reactive	NULL
with	NULL
activated	NULL
and	NULL
functionally	NULL
mature	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

II	NULL
.	NULL

Expression	NULL
of	NULL
Tac	NULL
antigen	NULL
on	NULL
activated	NULL
cytotoxic	NULL
killer	NULL
T	NULL
cells	NULL
,	NULL
suppressor	NULL
cells	NULL
,	NULL
and	NULL
on	NULL
one	NULL
of	NULL
two	NULL
types	NULL
of	NULL
helper	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
126	NULL
:	NULL
1398-1403	NULL
,	NULL
1981	NULL
.	NULL

Depper	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Leonard	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Waldmann	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
Blockade	NULL
of	NULL
the	NULL
interleukin-2	NULL
receptor	NULL
by	NULL
anti-	NULL
Tac	NULL
antibody	NULL
:	NULL
inhibition	NULL
of	NULL
human	NULL
lympho-cyte	NULL
activation	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
131	NULL
:	NULL
690-696	NULL
,	NULL
1983	NULL
.	NULL

Wakimann	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
,	NULL
Sarin	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
Saxinger	NULL
,	NULL
C.	NULL
,	NULL
Blayney	NULL
,	NULL
W.	NULL
,	NULL
Blattner	NULL
,	NULL
W.	NULL
A.	NULL
,	NULL
Gotdman	NULL
,	NULL
C.	NULL
K.	NULL
,	NULL
Bongiovanni	NULL
,	NULL
K.	NULL
,	NULL
Sharrow	NULL
,	NULL
S.	NULL
,	NULL
Depper	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Leonard	NULL
,	NULL
W.	NULL
,	NULL
Uchiyama	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Gallo	NULL
,	NULL
R.	NULL
C.	NULL
Functional	NULL
and	NULL
phenotypic	NULL
comparison	NULL
of	NULL
human	NULL
T	NULL
cell	NULL
leukemia/lymphoma	NULL
virus	NULL
negative	NULL
Sézary	NULL
leukemia	NULL
and	NULL
their	NULL
distinction	NULL
using	NULL
anti-Tac	NULL
,	NULL
monoclonal	NULL
antibody	NULL
identifying	NULL
the	NULL
human	NULL
receptor	NULL
for	NULL
T	NULL
cell	NULL
growth	NULL
factor	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
73	NULL
:	NULL
1711-1718	NULL
,	NULL
1984	NULL
.	NULL

Gallo	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
and	NULL
Wong-Staal	NULL
,	NULL
F.	NULL
Retroviruses	NULL
as	NULL
etiologic	NULL
agents	NULL
of	NULL
some	NULL
animal	NULL
and	NULL
human	NULL
leukemias	NULL
and	NULL
lymphomas	NULL
and	NULL
as	NULL
tools	NULL
for	NULL
elucidating	NULL
the	NULL
molecular	NULL
mechanism	NULL
of	NULL
leukemogenesis	NULL
.	NULL

Blood	NULL
,	NULL
60	NULL
:	NULL
545-557	NULL
,	NULL
1982	NULL
.	NULL

Mathieson	NULL
,	NULL
B.	NULL
J.	NULL
,	NULL
Sharrow	NULL
,	NULL
S.	NULL
O.	NULL
,	NULL
Campbell	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
and	NULL
Asofsky	NULL
,	NULL
R.	NULL
LyT	NULL
differentiated	NULL
thymocytes	NULL
sub-population	NULL
detected	NULL
by	NULL
flow	NULL
microfluorometry	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
277	NULL
:	NULL
478-480	NULL
,	NULL
1979	NULL
.	NULL

Haynes	NULL
,	NULL
B.	NULL
F.	NULL
,	NULL
Metzgar	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
Minna	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
and	NULL
Bunn	NULL
,	NULL
P.	NULL
A.	NULL
Phenotypic	NULL
characterization	NULL
of	NULL
cutaneous	NULL
T-cell	NULL
lymphoma	NULL
.	NULL

Use	NULL
of	NULL
monoclonal	NULL
antibodies	NULL
to	NULL
compare	NULL
with	NULL
other	NULL
malignant	NULL
T	NULL
cells	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
304	NULL
:	NULL
1319-1323	NULL
,	NULL
1981	NULL
.	NULL

Polsky	NULL
,	NULL
F.	NULL
,	NULL
Edgell	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
Seidman	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
and	NULL
Leder	NULL
,	NULL
P.	NULL
High	NULL
capacity	NULL
get	NULL
preparative	NULL
electrophoresis	NULL
for	NULL
purification	NULL
of	NULL
fragments	NULL
of	NULL
genomic	NULL
DNA	NULL
.	NULL

Anal	NULL
.	NULL

Biochem	NULL
.	NULL

,	NULL
87	NULL
:	NULL
397-410	NULL
,	NULL
1978	NULL
.	NULL

Renard	NULL
,	NULL
G.	NULL
,	NULL
Stark	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Waht	NULL
,	NULL
G.	NULL
M.	NULL
Detection	NULL
of	NULL
specific	NULL
RNAs	NULL
or	NULL
specific	NULL
19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28.	NULL
fragments	NULL
of	NULL
DNA	NULL
by	NULL
fractionation	NULL
in	NULL
gels	NULL
and	NULL
transfer	NULL
of	NULL
diazobenzyloxymethyl	NULL
paper	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

,	NULL
68	NULL
:	NULL
220-242	NULL
,	NULL
1980	NULL
.	NULL

Hedrick	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Cohen	NULL
,	NULL
D.	NULL
I.	NULL
,	NULL
Nielsen	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
and	NULL
Davis	NULL
,	NULL
M.	NULL
M.	NULL
Isolation	NULL
of	NULL
cDNA	NULL
clones	NULL
encoding	NULL
T-cell	NULL
specific	NULL
membrane-associated	NULL
proteins	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
308	NULL
:	NULL
149-153	NULL
,	NULL
1984	NULL
.	NULL

Depper	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Leonard	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Kronke	NULL
,	NULL
M.	NULL
,	NULL
Waldmann	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
Augmentation	NULL
of	NULL
T-cell	NULL
growth	NULL
factor	NULL
expression	NULL
in	NULL
HTLV-I	NULL
infected	NULL
human	NULL
leukemic	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
133	NULL
;	NULL
1691-1695	NULL
,	NULL
1984	NULL
.	NULL

Leonard	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Depper	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Roth	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Rudikoff	NULL
,	NULL
S.	NULL
,	NULL
Waldmann	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
Aberrant	NULL
T-cell	NULL
growth	NULL
factor	NULL
(	NULL
TCGF	NULL
)	NULL
receptors	NULL
on	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
(	NULL
HTLV	NULL
)	NULL
infected	NULL
leukemic	NULL
cells	NULL
.	NULL

Clin	NULL
.	NULL

Res	NULL
.	NULL

,	NULL
37	NULL
:	NULL
348A	NULL
,	NULL
1983	NULL
.	NULL

Leonard	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Depper	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Waldmann	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
A	NULL
monecional	NULL
antibody	NULL
to	NULL
the	NULL
human	NULL
receptor	NULL
for	NULL
T-cell	NULL
growth	NULL
factor	NULL
.	NULL

in	NULL
:	NULL
M.	NULL
F.	NULL
Greaves	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Monoclonal	NULL
Antibodies	NULL
to	NULL
Receptors	NULL
:	NULL
Probes	NULL
for	NULL
Receptor	NULL
Structure	NULL
and	NULL
Function	NULL
;	NULL
Receptors	NULL
and	NULL
Recognition	NULL
,	NULL
Ser	NULL
.	NULL

B	NULL
,	NULL
Vol	NULL
.	NULL

17	NULL
,	NULL
pp	NULL
.	NULL

45-46	NULL
.	NULL

London	NULL
:	NULL
Chapman	NULL
and	NULL
Hall	NULL
,	NULL
1984	NULL
.	NULL

Uchiyama	NULL
,	NULL
T.	NULL
,	NULL
Wano	NULL
,	NULL
Y.	NULL
,	NULL
Tsudo	NULL
,	NULL
M.	NULL
,	NULL
Umadome	NULL
,	NULL
H.	NULL
,	NULL
Hori	NULL
,	NULL
T.	NULL
,	NULL
Tamori	NULL
,	NULL
S.	NULL
,	NULL
Yodoi	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Maeda	NULL
,	NULL
M.	NULL
Abnormal	NULL
expression	NULL
of	NULL
Tac	NULL
antigen	NULL
(	NULL
IL-2	NULL
receptor	NULL
)	NULL
in	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
.	NULL

/n	NULL
:	NULL
M.	NULL
Miwa	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Retroviruses	NULL
in	NULL
Human	NULL
Lymphoma/Leuke-mia	NULL
:	NULL
The	NULL
Fifteenth	NULL
International	NULL
Symposium	NULL
of	NULL
the	NULL
Princess	NULL
Takamatsu	NULL
Cancer	NULL
Research	NULL
Fund	NULL
.	NULL

Tokyo	NULL
:	NULL
Japan	NULL
Scientific	NULL
Society	NULL
Press	NULL
,	NULL
in	NULL
press	NULL
,	NULL
1985	NULL
.	NULL

Tsudo	NULL
,	NULL
M.	NULL
,	NULL
Uchiyama	NULL
,	NULL
T.	NULL
,	NULL
Takatsuki	NULL
,	NULL
K.	NULL
,	NULL
Uchino	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Yodoi	NULL
,	NULL
J.	NULL
Modulation	NULL
of	NULL
Tac	NULL
antigen	NULL
on	NULL
activated	NULL
human	NULL
T	NULL
cells	NULL
by	NULL
anti-Tac	NULL
monoclonal	NULL
antibody	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
129	NULL
;	NULL
592-595	NULL
,	NULL
1982	NULL
.	NULL

Sodorski	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Rosen	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
and	NULL
Haseltine	NULL
,	NULL
W.	NULL
A.	NULL
Transacting	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
of	NULL
human	NULL
T	NULL
lymphotrophic	NULL
virus	NULL
infected	NULL
cells	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
,	NULL
225	NULL
:	NULL
381-385	NULL
,	NULL
1984	NULL
.	NULL

Seiki	NULL
,	NULL
M.	NULL
,	NULL
Hattori	NULL
,	NULL
S.	NULL
,	NULL
Hirayama	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Yoshida	NULL
,	NULL
M.	NULL
Human	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
:	NULL
complete	NULL
nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
provirus	NULL
genome	NULL
integrated	NULL
in	NULL
leukemia	NULL
cell	NULL
DNA	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
80	NULL
:	NULL
3618-3622	NULL
,	NULL
1983	NULL
.	NULL

Leonard	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Depper	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
Rudikoff	NULL
,	NULL
S.	NULL
,	NULL
Pumphrey	NULL
,	NULL
J.	NULL
,	NULL
Robb	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Kronke	NULL
,	NULL
M.	NULL
,	NULL
Svetlik	NULL
,	NULL
P.	NULL
B.	NULL
,	NULL
Peffer	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
Waldmann	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
Molecular	NULL
cloning	NULL
and	NULL
expression	NULL
of	NULL
cDNAs	NULL
for	NULL
the	NULL
human	NULL
interleukin-2	NULL
receptor	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
311	NULL
:	NULL
626-631	NULL
,	NULL
1984	NULL
.	NULL

Kronke	NULL
,	NULL
M.	NULL
,	NULL
Depper	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Leonard	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Vitetta	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
Waldmann	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
Anti-Tac-ricin	NULL
A	NULL
conjugates	NULL
selectively	NULL
inhibit	NULL
protein	NULL
synthesis	NULL
in	NULL
human	NULL
T-cell	NULL
leukemia/ymphoma	NULL
virus	NULL
infected	NULL
leukemic	NULL
T	NULL
cells	NULL
.	NULL

Blood	NULL
,	NULL
65	NULL
:	NULL
1416-1421	NULL
,	NULL
1985.	NULL
.	NULL

FitzGerald	NULL
,	NULL
D.	NULL
J.	NULL
P.	NULL
,	NULL
Wakdimann	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
Willingham	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
and	NULL
Pastan	NULL
,	NULL
I.	NULL
Pseudomonas	NULL
exotoxin-anti-	NULL
T	NULL
ac	NULL
.	NULL

Cell-specific	NULL
immunotoxin	NULL
active	NULL
against	NULL
cells	NULL
expressing	NULL
the	NULL
human	NULL
T-cell	NULL
growth	NULL
factor	NULL
receptor	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
74	NULL
:	NULL
966-971	NULL
,	NULL
1984	NULL
.	NULL

CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

45	NULL
SEPTEMBER	NULL
1985	NULL
4562s	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1985	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAGR	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Cancer	NULL
Research	NULL
The	NULL
Journal	NULL
of	NULL
Cancer	NULL
Research	NULL
(	NULL
1916-1930	NULL
)	NULL
|	NULL
The	NULL
American	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1931-1940	NULL
)	NULL
Interleukin	NULL
2	NULL
Receptor	NULL
(	NULL
Tac	NULL
Antigen	NULL
)	NULL
Expression	NULL
in	NULL
HTLV-l-associated	NULL
Adult	NULL
T-Cell	NULL
Leukemia	NULL
Thomas	NULL
A.	NULL
Waldmann	NULL
,	NULL
Dan	NULL
L.	NULL
Longo	NULL
,	NULL
Warren	NULL
J.	NULL
Leonard	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Cancer	NULL
Res	NULL
1985	NULL
;	NULL
45:4559s-4562s	NULL
.	NULL

Updated	NULL
version	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/45/9	NULL
_	NULL
Supplement/4559s	NULL
E-mail	NULL
alerts	NULL
Reprints	NULL
and	NULL
Subscriptions	NULL
Permissions	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/45/9	NULL
_	NULL
Supplement/4559s	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1985	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

